cocktail

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 349 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

MCE Protease Inhibitor Cocktail (EDTA-Free, 100× in DMSO) is a blend of 6 pan-protease inhibitors for protection of protein integrity.

MCE Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) is a blend of 5 pan-protease inhibitors for protection of protein integrity.

MCE Protease Inhibitor Cocktail, Bacteria (EDTA-Free, 100× in DMSO) protects proteins from degradation by endogenous proteases released during protein extraction and purification.

Phosphatase Inhibitor Cocktail Ⅱ (100× in ddH₂O) is a blend of 5 phosphatase inhibitors that can broadly inhibit acid phosphatases, alkaline phosphatases, and protein tyrosine phosphatases (PTPs).

MCE Protease and Phosphatase Inhibitor Cocktail (EDTA-Free, 10× in ddH₂O) protects protein from degradation by endogenous proteases released during protein extraction and purification.

Phosphatase Inhibitor Cocktail I (100× in DMSO) is a blend of 2 phosphatase inhibitors that can effectively inhibit alkaline phosphatases and serine/threonine phosphatases. It is used to maintain the phosphorylation status of proteins.

Phosphatase Inhibitor Cocktail Ⅲ (100× in DMSO) is a blend of 3 phosphatase inhibitors that can effectively inhibit serine/threonine phosphatases and alkaline phosphatases. It is used to maintain the phosphorylation status of proteins.

MCE CEPT Cocktail is composed of CET small molecules (Chroman 1, Emricasan and Trans-ISRIB) and Polyamine Solution, and can effectively enhance cell survival and promote clonal growth of genetically stable hPSCs.

MCE Deacetylase Inhibitor Cocktail is a synergistic combination of chemicals designed to preserve the acetylation state of proteins.

MCE Kinase Inhibitor Cocktail controls the biological activity of kinases. This inhibitor is primarily used for Biochemicals applications.